Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPS804 Safety and PK in Late-stage CKD
NCT01806610Phase 2Withdrawn
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Aug 2013
- Primary completion
- Apr 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of setrusumab in chronic kidney disease (CKD), sponsored by Ultragenyx Pharmaceutical Inc.. Planned start Aug 2013; status: withdrawn.
02
Drugs
setrusumab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01806610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806610.